Univeristy College London Hospital
Welcome,         Profile    Billing    Logout  
 38 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Amy A
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26
SJATRT, NCT02114229: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Active, not recruiting
2
125
US
alisertib, methotrexate, MTX, cisplatin, Platinol-AQ, carboplatin, paraplatin, cyclophosphamide, cytoxan, etoposide, VP-16, Vepesid, Etoposide phosphate (Etopophos), topotecan, Hycamtin, vincristine, Oncovin, Surgical resection, surgical management, Radiation therapy, Craniospinal irradiation (CSI), Radiotherapy
St. Jude Children's Research Hospital, Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
09/25
09/27
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
NCT03128047: HUMC 1612: Optune NovoTTF-200A System

Active, not recruiting
1
7
US
Optune NovoTTF-200A System
Hackensack Meridian Health, NovoCure Ltd.
High Grade Glioma, Ependymoma
07/24
07/26
NCT05518838: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

No Longer Available
N/A
US
OKN-007
Oblato, Inc.
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
 
 
Swanton, Charles
MERMAID-2, NCT04642469 / 2020-000612-30: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Jan 2024 - Dec 2024: Data from MERMAID-2 trial for NSCLC
Completed
3
30
Europe, Canada, Japan, US, RoW
Durvalumab, Medi4736, Placebo
AstraZeneca
Carcinoma, Non- Small Cell Lung
05/23
01/24
MERMAID-1, NCT04385368 / 2020-000556-35: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Hourglass Jan 2024 - Dec 2024 : Results from MERMAID-1 trial for stage II-III NSCLC
Jan 2023 - Dec 2024: Regulatory submission for adjuvant NSCLC (based on MERMAID-1 trial)
Completed
3
89
Europe, Canada, Japan, US, RoW
Durvalumab + SoC chemotherapy, MEDI4736, Placebo + SoC chemotherapy, Placebo
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/23
08/23
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26

Download Options